The company
Definium Therapeutics, Inc. - Common Shares
DFTX · Nasdaq
DFTX stood above a rising 150-day average in 52 of the last 52 weekly readings, every one of them. It is 1.2% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Just started moving
- Weeks in an uptrend
- 52 in a row
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $13.4M
- Officials’ trades on record
- 0
- Institutions holding
- 346 (+110)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 52 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Brandi RobertsChief Financial Officer | sold | 3,377at $36.57 | 25 Sep 2026filed 29 Sep 2026 |
| Mark SullivanChief Legal Officer | sold | 14,051at $36.57 | 25 Sep 2026filed 29 Sep 2026 |
| Matthew T. WileyChief Commercial Officer | sold | 3,097at $36.57 | 25 Sep 2026filed 29 Sep 2026 |
| Robert BarrowChief Executive Officer | sold | 31,550at $36.57 | 25 Sep 2026filed 29 Sep 2026 |
| Daniel KarlinChief Medical Officer | sold | 10,853at $36.57 | 25 Sep 2026filed 29 Sep 2026 |
| Robert BarrowChief Executive Officer | sold | 19,023at $37.94 | 3 Sep 2026filed 4 Sep 2026 |
| Matthew T. WileyChief Commercial Officer | sold | 2,867at $45.03 | 25 Jun 2026filed 26 Jun 2026 |
| Robert BarrowChief Executive Officer | sold | 29,208at $45.03 | 25 Jun 2026filed 26 Jun 2026 |
| Brandi RobertsChief Financial Officer | sold | 3,013at $45.03 | 25 Jun 2026filed 26 Jun 2026 |
| Daniel KarlinChief Medical Officer | sold | 10,035at $45.03 | 25 Jun 2026filed 26 Jun 2026 |
| Mark SullivanChief Legal Officer | sold | 13,008at $45.03 | 25 Jun 2026filed 26 Jun 2026 |
| Robert BarrowChief Executive Officer | sold | 24,431at $18.47 | 25 Mar 2026filed 26 Mar 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.added · filed 7 Aug 2026 | 11,232,834$528.4M | +2,752,604+32.5% |
| Avoro Capital Advisors LLCadded · filed 14 Aug 2026 | 7,188,888$338.2M | +2,188,888+43.8% |
| Driehaus Capital Management LLCadded · filed 14 Aug 2026 | 6,845,276$322.0M | +933,387+15.8% |
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 5,615,645$264.0M | +5,615,645 |
| Capital World Investorsnew · filed 12 Aug 2026 | 5,367,723$252.5M | +5,367,723 |
| FMR LLCadded · filed 13 Aug 2026 | 4,752,921$223.6M | +2,943,311+162.6% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 3,644,813$171.5M | +1,149,414+46.1% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 3,065,390$144.2M | +593,517+24.0% |
| Capital International Investorsnew · filed 12 Aug 2026 | 2,963,410$139.4M | +2,963,410 |
| Octagon Capital Advisors LPadded · filed 14 Aug 2026 | 2,950,000$138.8M | +510,000+20.9% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.